Evidence map›Paper›PMID 40815454›Full record

ArticleDermatology and therapy2025

The Lived Experience of Patients Diagnosed with Vitiligo and a Preliminary Conceptual Disease Model: Insights from Patients, Patient Advocates, and Clinicians.

Khaled Ezzedine, Ahmed M Soliman, Mary Kathleen Ladd, Stavonnie Patterson, Rohini Sen, Sarah Ofori, Karin S Coyne, Robin Pokrzywinski

Abstract read
In one paragraph

Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Khaled EzzedineDepartment of Dermatology, AP-HP, Henri Mondor University Hospital, UPEC, Créteil, France. khaled.ezzedine@aphp.fr.ORCID http://orcid.org/0000-0002-5468-4589
Ahmed M SolimanAbbVie, Inc., North Chicago, IL, USA.
Mary Kathleen LaddEvidera, Wilmington, NC, USA.
Stavonnie PattersonAbbVie, Inc., North Chicago, IL, USA.
Rohini SenAbbVie, Inc., North Chicago, IL, USA.
Sarah Ofori, Chicago, IL, USA.
Karin S CoyneEvidera, Wilmington, NC, USA.
Robin PokrzywinskiEvidera, Wilmington, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with vitiligo experience high disease and psychosocial burden, and dissatisfaction with current treatment options, highlighting a need to understand the disease from a patient perspective. This study gathered insights from key opinion leaders (KOLs) and patient advocates on a conceptual disease model of vitiligo and gained patient perspectives through qualitative interviews on the disease burden and concepts important to patients with nonsegmental vitiligo (NSV), and what degree and anatomical location of repigmentation may constitute a meaningful change with treatment.

methodsThis cross-sectional, observational study involved virtual, semi-structured, qualitative interviews with expert KOLs treating patients with vitiligo, patient advocates, and patients diagnosed with NSV.

resultsPatient advocates (n = 5) and KOLs (n = 6) felt that the conceptual disease model comprehensively captured the signs, symptoms, and impact of vitiligo, and had minor changes including reordering symptoms. Of 22 patients interviewed, most experienced depigmentation on their arms, trunk, hands, feet; and 86.4% had vitiligo on their face. The most frequently reported sign or symptom was increased sensitivity to the sun (82%). Patients reported that vitiligo broadly impacts many facets of life, most commonly emotional well-being (82%). Patients reported that perceived treatment success is driven by the extent of vitiligo repigmentation, especially on the face and hands, and would consider 20-25% repigmentation a meaningful improvement.

conclusionThis study provides insight into the lived experience of patients with NSV, and alignment from patient advocates and KOLs on the conceptual disease model of vitiligo. The findings increase our understanding and inform vitiligo clinical studies.

Indexed as

Non-segmental vitiligoPatient-reported outcomesQualitative interviews

Identifiers

PMID40815454
PMCPMC12454719

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.